John M. Kovarik - Concepedia

Author

John M. Kovarik

Also Known As

Anne Karara, J KOVARIK, J Kovarik, J Kovarík, J Kovarĭk, J M Kovarik, J M. Kovarik, J. Kovarik, J. M. Kovarik, J.M Kovarik

168

Publications

7.5K

Citations

H-Index

114

Concepts

All Affiliations

Novartis (Switzerland)Novartis (United States)Novartis (France)

About

John M. Kovarik is an author at Novartis (Switzerland) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	39	3.3K
2	Health Sciences	5	5	263
3	Allergy	4	4	1K
4	Engineering	1	1	54
5	Natural Sciences	1	1	54

John M. Kovarik

Publications

6.8K

Citations

H-Index

Page 1

	Year	Citations
mTOR inhibition improves immune function in the elderly Joan B. Mannick, Giuseppe Del Giudice, Maria Lattanzi, Science Translational Medicine AgingImmunologyImmunotherapyImmune DysregulationInflammation	2014	735
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors Anne O’Donnell, Sandrine Faivre, Howard A. Burris, Journal of Clinical Oncology	2008	476
Reduced Inter- and Intraindividual Variability in Cyclosporine Pharmacokinetics from a Microemulsion Formulation John M. Kovarik, Edgar A. Mueller, Klaus Kutz, Journal of Pharmaceutical Sciences Pharmaceutical SciencePhysiologically-based Pharmacokinetic ModelingMedicinePharmacotherapyMicroemulsion Formulation	1994	297
CYCLOSPORINE PHARMACOKINETICS AND VARIABILITY FROM A MICROEMULSION FORMULATION—A MULTICENTER INVESTIGATION IN KIDNEY TRANSPLANT PATIENTS John M. Kovarik, Edgar A. Mueller, Johannes B. van Bree, Transplantation Pharmaceutical ScienceUrologyPharmacokinetic ModelingCommercial FormulationChronic Kidney Disease	1994	251
Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data Chiaki Tanaka, Terence O’Reilly, John M. Kovarik, Journal of Clinical Oncology	2008	209
Influence of a Fat-Rich Meal on the Pharmacokinetics of a New Oral Formulation of Cyclosporine in a Crossover Comparison with the Market Formulation Edgar A. Mueller, John M. Kovarik, Johannes B. van Bree, Pharmaceutical Research	1994	172
PHARMACOKINETICS AND TOLERABILITY OF A MICROEMULSION FORMULATION OF CYCLOSPORINE IN RENAL ALLOGRAFT RECIPIENTS—A CONCENTRATION-CONTROLLED COMPARISON WITH THE COMMERCIAL FORMULATION Edgar A. Mueller, John M. Kovarik, Johannes B. van Bree, Transplantation Pharmaceutical SciencePharmacokinetic ModelingAllergyMedicineImmunosuppressive Therapy	1994	145
Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range John M. Kovarik, Bruce Kaplan, Hélio Tedesco‐Silva, Transplantation	2002	139
Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation Claus Moser, Gudrun Pohl, Isabella Haslinger, Nephrology Dialysis Transplantation	2008	135
DISPOSITION OF BASILIXIMAB, AN INTERLEUKIN-2 RECEPTOR MONOCLONAL ANTIBODY, IN RECIPIENTS OF MISMATCHED CADAVER RENAL ALLOGRAFTS1 John M. Kovarik, P. Wolf, J.M. Cisterne, Transplantation	1997	126

Page 1